SG169373A1 - Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells - Google Patents

Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells

Info

Publication number
SG169373A1
SG169373A1 SG201100772-1A SG2011007721A SG169373A1 SG 169373 A1 SG169373 A1 SG 169373A1 SG 2011007721 A SG2011007721 A SG 2011007721A SG 169373 A1 SG169373 A1 SG 169373A1
Authority
SG
Singapore
Prior art keywords
mammalian cells
drug delivery
minicells
targeted
vitro
Prior art date
Application number
SG201100772-1A
Other languages
English (en)
Inventor
Himanshu Brahmbhatt
Jennifer Macdiarmid
Original Assignee
Engeneic Molecular Delivery Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engeneic Molecular Delivery Pty Ltd filed Critical Engeneic Molecular Delivery Pty Ltd
Publication of SG169373A1 publication Critical patent/SG169373A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG201100772-1A 2004-02-02 2005-01-27 Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells SG169373A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54059004P 2004-02-02 2004-02-02

Publications (1)

Publication Number Publication Date
SG169373A1 true SG169373A1 (en) 2011-03-30

Family

ID=34885947

Family Applications (3)

Application Number Title Priority Date Filing Date
SG200705648-4A SG135175A1 (en) 2004-02-02 2005-01-27 Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
SG200705647-6A SG135174A1 (en) 2004-02-02 2005-01-27 Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
SG201100772-1A SG169373A1 (en) 2004-02-02 2005-01-27 Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG200705648-4A SG135175A1 (en) 2004-02-02 2005-01-27 Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
SG200705647-6A SG135174A1 (en) 2004-02-02 2005-01-27 Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells

Country Status (19)

Country Link
US (3) US9867785B2 (es)
EP (2) EP2992901B1 (es)
JP (2) JP5060787B2 (es)
CN (2) CN1925873B (es)
AU (2) AU2005215254B2 (es)
CA (2) CA2556248C (es)
DK (2) DK1718338T3 (es)
ES (2) ES2544652T3 (es)
HK (1) HK1155665A1 (es)
HR (1) HRP20150828T8 (es)
HU (1) HUE025292T2 (es)
ME (1) ME02251B (es)
NZ (1) NZ549139A (es)
PL (1) PL1718338T3 (es)
PT (1) PT1718338E (es)
RS (1) RS54149B1 (es)
SG (3) SG135175A1 (es)
SI (1) SI1718338T1 (es)
WO (1) WO2005079854A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986736B2 (en) 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
AU2004249172A1 (en) 2003-06-24 2004-12-29 Baxter International Inc. Specific delivery of drugs to the brain
ME02251B (me) 2004-02-02 2015-12-31 Engeneic Molecular Delivery Pty Ltd Kompozicije i postupci in vitro i in vivo, ciljanog oslobađanja leka u ćelijama sisara, preko intaktnih minićelija izvedenih iz bakterija
EP1763576A2 (en) 2004-06-15 2007-03-21 Baxter International Inc. Ex-vivo application of solid microparticulate therapeutic agents
WO2006021894A2 (en) * 2004-08-26 2006-03-02 Engeneic Gene Therapy Pty Limited Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells
CN101715489B (zh) 2007-03-30 2016-05-25 因詹尼克分子递送控股有限公司 用于体内递送至哺乳动物细胞的、包含无质粒的功能性核酸的、源自细菌的完整小细胞
BRPI0817261A2 (pt) 2007-09-24 2015-06-30 Univ Queensland Vesícula de entrega molecular
SG10202011946PA (en) 2008-01-22 2020-12-30 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
WO2009111638A1 (en) 2008-03-05 2009-09-11 Baxter International Inc. Compositions and methods for drug delivery
AU2009262306B2 (en) 2008-06-25 2015-07-09 Vaxiion Therapeutics, Llc Regulated genetic suicide mechanism compositions and methods
US10952965B2 (en) 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
WO2011002239A2 (ko) 2009-07-01 2011-01-06 주식회사이언메딕스 포유류의 유핵세포에서 유래된 마이크로베시클 및 이의 용도
IT1401457B1 (it) * 2010-06-11 2013-07-26 Fond I R C C S Istituto Neurologico Carlo Besta Carrier di tipo cellulare per il trasporto mirato di almeno una molecola e/o almeno un composto molecolare ad almeno una cellula bersaglio in un mammifero umano o non umano
US9149542B2 (en) 2010-07-01 2015-10-06 Aeon Medix Inc. Microvesicles derived from cell protoplast and use thereof
WO2012112696A1 (en) * 2011-02-15 2012-08-23 Vaxiion Therapeutics, Inc. Therapeutic compositions and methods for antibody and fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells
ES2843402T3 (es) * 2011-12-13 2021-07-16 Engeneic Molecular Delivery Pty Ltd Minicélulas intactas de origen bacteriano para la administración de agentes terapéuticos a tumores cerebrales
US9267108B2 (en) 2012-10-02 2016-02-23 Vaxiion Therapeutics, Llc Immunomodulatory minicells and methods of use
WO2014055638A1 (en) * 2012-10-03 2014-04-10 Waters Technologies Corporation Rapid analysis of steroids and steroid derivatives
US20160120818A1 (en) * 2013-02-07 2016-05-05 Glaxosmithline Biological Sa Pharmaceutical compositions comprising vesicles
WO2014199448A1 (ja) * 2013-06-11 2014-12-18 ハウスウェルネスフーズ株式会社 貪食細胞へ物質を送達する担体
CN105658233B (zh) 2013-10-04 2020-09-04 安吉尼科分子传输公司 使用携带药物的、双特异性配体靶向的微细胞和干扰素-γ的联合肿瘤治疗
CA2963218C (en) * 2014-10-03 2023-10-24 Engeneic Molecular Delivery Pty Ltd Enhanced loading of intact, bacterially derived vesicles with small molecule compounds
CN104388459B (zh) * 2014-10-29 2017-03-08 四川农业大学 使细菌自主产微细胞的方法及一株自产微细胞细菌突变株
KR101708424B1 (ko) 2015-03-04 2017-02-20 전남대학교산학협력단 코리네박테리움 속 박테리아 및 이로부터 유래된 미니셀 그리고 이의 용도
KR102687638B1 (ko) 2015-08-04 2024-07-22 벡션 테라퓨틱스 엘엘씨 이온화 방사선 조사 멸균된 박테리아 미니세포 기반 생물 약제
KR101858840B1 (ko) 2016-01-15 2018-05-16 단국대학교 천안캠퍼스 산학협력단 집먼지진드기 유래 알레르겐에 의한 과민반응 면역조절제
WO2017192863A1 (en) 2016-05-04 2017-11-09 L.E.A.F. Holdings Group Llc Targeted liposomal gemcitabine compositions and methods thereof
IL265855B1 (en) 2016-10-06 2024-08-01 Engeneic Molecular Delivery Pty Ltd Bacterial cell species for transporting nucleic acid adjuvants and methods of using them
EP3649242A2 (en) 2017-07-06 2020-05-13 National University of Singapore Methods of inhibiting cell proliferation and mettl8 activity
WO2019204154A1 (en) 2018-04-18 2019-10-24 Reyoung Corporation Compositions and methods for treating liver cancer
WO2019217164A1 (en) 2018-05-09 2019-11-14 Reyoung Corporation Compositions and methods for treating cancer and other diseases
WO2020021437A1 (en) 2018-07-23 2020-01-30 Engeneic Molecular Delivery Pty Ltd Compositions comprising bacterially derived minicells and methods of using the same
WO2020210378A1 (en) * 2019-04-08 2020-10-15 University Of Massachusetts Localization of payload delivery systems to tumor sites via beacon cell targeting
WO2020222161A1 (en) * 2019-05-01 2020-11-05 Engeneic Molecular Delivery Pty Ltd Compositions comprising bacterially derived intact minicells for theranostic applications
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN114053430A (zh) * 2020-07-29 2022-02-18 深圳先进技术研究院 一种负载纳米载药颗粒的细菌及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4496778A (en) 1983-10-03 1985-01-29 Exxon Research & Engineering Co. Process for the hydroxylation of olefins using molecular oxygen, an osmium containing catalyst, a copper Co-catalyst, and an aromatic amine based promoter
CA1270198A (en) 1984-08-08 1990-06-12 Marcel B. Bally Encapsulation of antineoplastic agents in liposomes
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) * 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
WO1996032930A1 (en) 1995-04-18 1996-10-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposome drug-loading method and composition
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
AU781598B2 (en) 1999-04-21 2005-06-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhibiting the function of polynucleotide sequences
AU2001294520A1 (en) 2000-08-21 2002-03-04 Clonex Development, Inc. Methods and compositions for increasing protein yield from a cell culture
CA2440649A1 (en) 2001-03-07 2002-09-19 Children's Medical Center Corporation Method to screen peptide display libraries using minicell display
US7011946B2 (en) 2001-05-22 2006-03-14 Trustees Of Tufts College In vivo assay for identification of antimicrobial agents
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
US20030166099A1 (en) * 2001-06-05 2003-09-04 Sabbadini Roger A. Minicells comprising membrane proteins
DK1446489T3 (da) * 2001-10-15 2012-05-14 Engeneic Molecular Delivery Pty Ltd Intakte miniceller som vektorer for DNA-overførsel og genterapi in vitro og in vivo
US20030207833A1 (en) 2002-02-25 2003-11-06 Neil Berkley Pharmaceutical compositions with minicells
EP2272946B9 (en) * 2002-02-25 2015-06-24 Vaxiion Therapeutics, LLC Minicell compositions and methods
US20030203481A1 (en) * 2002-02-25 2003-10-30 Surber Mark W. Conjugated minicells
US7611885B2 (en) 2003-06-24 2009-11-03 Engeneic Molecular Delivery Pty, Ltd. Pharmaceutically compatible method for purifying intact bacterial minicells
US9169495B2 (en) 2003-12-09 2015-10-27 Engeneic Molecular Delivery Pty Ltd. Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells
ME02251B (me) 2004-02-02 2015-12-31 Engeneic Molecular Delivery Pty Ltd Kompozicije i postupci in vitro i in vivo, ciljanog oslobađanja leka u ćelijama sisara, preko intaktnih minićelija izvedenih iz bakterija
WO2006021894A2 (en) 2004-08-26 2006-03-02 Engeneic Gene Therapy Pty Limited Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells
US20090123426A1 (en) 2004-12-17 2009-05-14 Chiang Li Compositions for Bacterial Mediated Gene Silencing and Methods of Using the Same
AU2007278899B2 (en) 2006-06-23 2012-09-06 Engenelc Molecular Delivery Pty. Ltd. Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells

Also Published As

Publication number Publication date
CN102028953B (zh) 2013-10-30
DK2992901T3 (da) 2020-01-27
HUE025292T2 (en) 2016-02-29
HRP20150828T8 (hr) 2016-04-22
CA2556248A1 (en) 2005-09-01
JP5060787B2 (ja) 2012-10-31
SG135174A1 (en) 2007-09-28
EP1718338B1 (en) 2015-05-06
SI1718338T1 (sl) 2015-09-30
EP2992901B1 (en) 2019-10-23
ME02251B (me) 2015-12-31
PL1718338T3 (pl) 2015-12-31
EP1718338A1 (en) 2006-11-08
US10799461B2 (en) 2020-10-13
US20180133163A1 (en) 2018-05-17
CN1925873A (zh) 2007-03-07
RS54149B1 (en) 2015-12-31
CN102028953A (zh) 2011-04-27
CA2788707A1 (en) 2005-09-01
AU2010200599A1 (en) 2010-03-11
CA2788707C (en) 2014-02-25
US20180280311A1 (en) 2018-10-04
CA2556248C (en) 2013-04-02
JP2011178798A (ja) 2011-09-15
DK1718338T3 (en) 2015-08-10
HK1155665A1 (en) 2012-05-25
US20140220116A1 (en) 2014-08-07
WO2005079854A1 (en) 2005-09-01
PT1718338E (pt) 2015-09-21
AU2005215254B2 (en) 2009-11-12
AU2005215254A1 (en) 2005-09-01
US9867785B2 (en) 2018-01-16
ES2544652T3 (es) 2015-09-02
JP5571031B2 (ja) 2014-08-13
EP2992901A1 (en) 2016-03-09
NZ549139A (en) 2009-11-27
HRP20150828T1 (en) 2015-09-11
CN1925873B (zh) 2011-02-09
EP1718338A4 (en) 2009-07-22
ES2765426T3 (es) 2020-06-09
JP2007534667A (ja) 2007-11-29
SG135175A1 (en) 2007-09-28
AU2010200599B2 (en) 2011-09-22

Similar Documents

Publication Publication Date Title
SG169373A1 (en) Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
WO2008012695A3 (en) Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
Nishimoto et al. Effect of chondroitin sulfate and hyaluronic acid on gene expression in a three-dimensional culture of chondrocytes
MX2023006056A (es) Nanoparticulas lipidicas para suministro de acidos nucleicos y metodos de uso de las mismas.
HK1095090A1 (en) Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells
NZ611662A (en) Peptide-based in vivo sirna delivery system
EP1791959A4 (en) DISPOSAL OF FUNCTIONAL NUCLEIC ACIDS ON MAMMALIAN CELLS OVER BACTERIA ORIGINAL INTACT MINIMIZERS
WO2012112696A8 (en) Therapeutic compositions and methods for antibody and fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells
EP3778917A3 (en) Multispecific antibodies, antibody analogs, compositions, and methods
CA2600418A1 (en) Stabilized aptamers to psma and their use as prostate cancer therapeutics
NZ601737A (en) Compositions for targeted delivery of sirna
HRP20170662T1 (hr) Nedirnute ministanice, izvedene iz bakterija, koje sadrže regulatornu rnk
WO2008116195A3 (en) Compositions comprising an sglt2 ingibitor for treating obesity
WO2004076631A3 (en) Biologically active native biomatrix composition
WO2008079973A9 (en) EGF RECEPTOR BINDING PEPTIDES AND USES THEREOF
ATE547123T1 (de) Antikörper-rnase-konjugat
MY146518A (en) Methods to culture circovirus.
TR201904207T4 (tr) Olgun dendritik hücrelerin hazırlanması için bileşimler.
MX2009008030A (es) Liberacion controlada de activos en la piel.
BRPI0510257A (pt) uso de peptìdeos kikvav na preparação de composições cosméticas para melhoria da firmeza da pele através do aumento da adesão celular
WO2009059309A3 (en) Furin-cleavable peptide linkers for drug-ligand conjugates
MX2009010689A (es) Formulaciones novedosas para el suministro de agentes terapeuticos de peptidos antivirales.
WO2023107593A3 (en) In vivo delivery to immune cells
WO2009053718A3 (en) Immuno-modulatory composition
WO2004030621A3 (en) Method of treating cancer using adenosine and its analogs